Spots Global Cancer Trial Database for A Study of SGN-B6A in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SGN-B6A in Advanced Solid Tumors
Official Title: A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Study ID: NCT04389632
Conditions
Study Description
Brief Summary: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
Providence Portland Medical Center, Portland, Oregon, United States
Sanford Cancer Center, Sioux Falls, South Dakota, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Vista Oncology Inc PS, Olympia, Washington, United States
Institut Gustave Roussy, Villejuif Cedex, Other, France
Hospital HM Nou Delfos, Barcelona, Other, Spain
Hospital Universitari Vall d'Hebron, Barcelona, Other, Spain
Elche General University Hospital, Elche, Other, Spain
Hospital Universitario De Jerez, Jerez de la Frontera, Other, Spain
Hospital Universitario Ramon y Cajal Servicio de Oncologia Medica Oficina de Ensayos Clinicos, Madrid, Other, Spain
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Other, Spain
Hospital Universitario Marques de Valdecilla, Santander, Other, Spain
University Hospital Lausanne CHUV, Lausanne, Other, Switzerland
Sarah Cannon Research Institute UK, London, Other, United Kingdom
The Royal Marsden Hospital (Surrey), Sutton, Other, United Kingdom
Contact Details
Name: Medical Monitor
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
